{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:33:39Z","timestamp":1793572419491,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rituximab is a chimeric human-mouse immunoglobulin monoclonal antibody with high affinity for CD20 surface antigens expressed by pre-B and B cells that is commonly used as the mainstay for the treatment of B cell non-Hodgkin\u2019s lymphomas, including diffuse large B-cell lymphoma (DLBCL). As the drug has become more widely used, rituximab associated Interstitial Lung disease (RTX-ILD) is being recognized as potential complication (Non-infectious pulmonary toxicity of rituximab: a systematic review| Rheumatology| Oxford Academic).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case report<\/jats:title>\n            <jats:p>We discuss a 73-year-old woman with newly diagnosed DLBCL who underwent chemotherapy and immunotherapy with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulphate, and prednisone (R-CHOP). Following her initial rituximab infusion, she developed shortness of breath, chills, rigors, flushing, and agitation. The rituximab infusion was paused, and hypersensitivity reaction medications were given per protocol. The infusion was resumed at a slower rate. Two weeks after initial infusion, she was hospitalized for shortness of breath and hypoxemia to 88% on pulse oximeter requiring 2\u00a0L of nasal cannula oxygen. Chest imaging showed new diffuse ground glass opacities (GGOs) on top of apical scarring, upper lobe emphysema, and few calcified granulomas. Patient underwent bronchoscopy for bronchoalveolar lavage (BAL) which was negative for infections and malignancy. Given the temporal relationship, chemotherapy induced lung injury was high on the differential, with rituximab being the possible offending agent. She was started on prednisone 60 milligram for 5 days with a follow up chest imaging showing resolution of the acute GGO. Her O2 requirements decreased from 3\u00a0L to 1\u00a0L and she was sent home with oxygen. Given the curative intent of R-CHOP, after shared decision making with the patient and her medical team, a treatment plan with a longer course of high and low prednisone was incorporated as part of her chemotherapy session. She was able to successfully finish her treatment with no additional episode, at which point she was able to be successfully tapered off her prednisone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion <\/jats:title>\n            <jats:p>Rituximab induced ILD is rare but given its severity requires a high index of suspicion for diagnosis. Given the potential for long term complication, once suspected, treatment should be discontinued. Here we detail how a prolonged steroid course could be used as adjunct therapy of ILD if therapy with rituximab is considered curative and essential.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Rituximab and Cyclophosphamide are well described causes of acute pneumonitis post R-CHOP administration. Given curative effect of R-CHOP, careful changes in management plan and co-treatment with steroids could help preserve lung function while allowing for full continuation of the chemotherapy regimen.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12890-025-03802-x","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:25:35Z","timestamp":1753698335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab induced lung injury"],"prefix":"10.1186","volume":"25","author":[{"given":"Rohit","family":"Chari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmna","family":"Abdelghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaine","family":"Kenaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"3802_CR1","unstructured":"Non-infectious pulmonary toxicity of rituximab: a systematic review| Rheumatology| Oxford Academic. Accessed April 11. 2024. https:\/\/academic.oup.com\/rheumatology\/article\/51\/4\/653\/1802004?login=false."},{"key":"3802_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","volume":"8","author":"TM Pierpont","year":"2018","unstructured":"Pierpont TM, Limper CB, Richards KL. Past, present, and future of Rituximab-The world\u2019s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. https:\/\/doi.org\/10.3389\/fonc.2018.00163.","journal-title":"Front Oncol"},{"key":"3802_CR3","doi-asserted-by":"publisher","unstructured":"Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematol Am Soc Hematol Educ Program Published Online 2005:329\u201334. https:\/\/doi.org\/10.1182\/asheducation-2005.1.329.","DOI":"10.1182\/asheducation-2005.1.329"},{"key":"3802_CR4","doi-asserted-by":"publisher","first-page":"iv27","DOI":"10.1093\/annonc\/mdr167","volume":"22","author":"PI Boffetta","year":"2011","unstructured":"Boffetta PI. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol. 2011;22:iv27\u201331. https:\/\/doi.org\/10.1093\/annonc\/mdr167.","journal-title":"Ann Oncol"},{"issue":"2","key":"3802_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/ard.2006.061002","volume":"66","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):143\u201350. https:\/\/doi.org\/10.1136\/ard.2006.061002.","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"3802_CR6","doi-asserted-by":"publisher","first-page":"6714","DOI":"10.3390\/jcm11226714","volume":"11","author":"JI Shin","year":"2022","unstructured":"Shin JI, Lee KH, Park S, et al. Systemic lupus erythematosus and lung involvement: A comprehensive review. J Clin Med. 2022;11(22):6714. https:\/\/doi.org\/10.3390\/jcm11226714.","journal-title":"J Clin Med"},{"issue":"6 Pt 1","key":"3802_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1164\/ajrccm.154.6.8970380","volume":"154","author":"SW Malik","year":"1996","unstructured":"Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1851\u20136. https:\/\/doi.org\/10.1164\/ajrccm.154.6.8970380.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3802_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1183\/09031936.00080209","volume":"35","author":"H Liot\u00e9","year":"2010","unstructured":"Liot\u00e9 H, Liot\u00e9 F, S\u00e9roussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: a systematic literature review. Eur Respir J. 2010;35(3):681\u20137. https:\/\/doi.org\/10.1183\/09031936.00080209.","journal-title":"Eur Respir J"},{"issue":"8","key":"3802_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.nmd.2022.05.013","volume":"32","author":"S Chaganti","year":"2022","unstructured":"Chaganti S, Hannaford A, Vucic S. Rituximab in chronic immune mediated neuropathies: a systematic review. Neuromuscul Disord. 2022;32(8):621\u20137. https:\/\/doi.org\/10.1016\/j.nmd.2022.05.013.","journal-title":"Neuromuscul Disord"},{"issue":"1\u20132","key":"3802_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jns.2014.07.055","volume":"345","author":"E Sala","year":"2014","unstructured":"Sala E, Robert-Varvat F, Paul S, Camdessanch\u00e9 JP, Antoine JC. Acute neurological worsening after rituximab treatment in patients with anti-MAG neuropathy. J Neurol Sci. 2014;345(1\u20132):224\u20137. https:\/\/doi.org\/10.1016\/j.jns.2014.07.055.","journal-title":"J Neurol Sci"},{"key":"3802_CR11","doi-asserted-by":"publisher","unstructured":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma| New England Journal of Medicine. Accessed May 16. 2025. https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa1805104","DOI":"10.1056\/NEJMoa1805104"},{"issue":"11","key":"3802_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood.V110.11.370.370","volume":"110","author":"KR Carson","year":"2007","unstructured":"Carson KR, Evens AM, Rosen ST, et al. Progressive multifocal leukoencephalopathy associated with rituximab treatment of B-Cell lymphoproliferative disorders: A report of 29 cases from the RADAR project. Blood. 2007;110(11):370. https:\/\/doi.org\/10.1182\/blood.V110.11.370.370.","journal-title":"Blood"},{"key":"3802_CR13","unstructured":"Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma: Leukemia & Lymphoma: Vol 49, No 9 - Get Access. Accessed April 11. 2024. https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428190802270886"},{"issue":"10","key":"3802_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ajh.20910","volume":"82","author":"SA Wagner","year":"2007","unstructured":"Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol. 2007;82(10):916\u20139. https:\/\/doi.org\/10.1002\/ajh.20910.","journal-title":"Am J Hematol"},{"issue":"3","key":"3802_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/01.TP.0000074700.30536.76","volume":"76","author":"HS Alho","year":"2003","unstructured":"Alho HS, Maasilta PK, Harjula ALJ, H\u00e4mm\u00e4inen P, Salminen J, Salminen US. Tumor necrosis factor-alpha in a Porcine bronchial model of obliterative bronchiolitis. Transplantation. 2003;76(3):516\u201323. https:\/\/doi.org\/10.1097\/01.TP.0000074700.30536.76.","journal-title":"Transplantation"},{"key":"3802_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fonc.2018.00288","volume":"8","author":"D Kumar","year":"2018","unstructured":"Kumar D, Xu ML. Microenvironment cell contribution to lymphoma immunity. Front Oncol. 2018;8:288. https:\/\/doi.org\/10.3389\/fonc.2018.00288.","journal-title":"Front Oncol"},{"key":"3802_CR17","doi-asserted-by":"publisher","unstructured":"Naqibullah M, Shaker SB, Bach KS, Bendstrup E. Rituximab-induced interstitial lung disease: five case reports. Eur Clin Respir J. 2015;2. https:\/\/doi.org\/10.3402\/ecrj.v2.27178.","DOI":"10.3402\/ecrj.v2.27178"},{"key":"3802_CR18","doi-asserted-by":"publisher","unstructured":"(PDF) Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies. ResearchGate Published Online Febr 28, 2025.https:\/\/doi.org\/10.1007\/s00277-024-06013-2.","DOI":"10.1007\/s00277-024-06013-2"},{"key":"3802_CR19","unstructured":"Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin\u2019s lymphoma - Biehn\u2013\u20092006 - Hematological Oncology - Wiley Online Library. Accessed April 11. 2024.\u00a0https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.799."},{"issue":"8","key":"3802_CR20","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3324\/haematol.12802","volume":"93","author":"L Nieuwenhuizen","year":"2008","unstructured":"Nieuwenhuizen L, Verzijlbergen FJ, Wiltink E, Grutters JC, Biesma DH. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin\u2019s lymphoma. Haematologica. 2008;93(8):1267\u20139. https:\/\/doi.org\/10.3324\/haematol.12802.","journal-title":"Haematologica"},{"key":"3802_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/978-3-642-15742-4_64","volume":"19","author":"Y Herishanu","year":"2010","unstructured":"Herishanu Y, Perry C, Polliack A. Rituximab-Related pulmonary toxicity. Pulm Involv patients hematol Malig. Published Online August. 2010;19:751\u20137. https:\/\/doi.org\/10.1007\/978-3-642-15742-4_64.","journal-title":"Published Online August"},{"issue":"1","key":"3802_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3324\/haematol.10561","volume":"92","author":"SJ Wu","year":"2007","unstructured":"Wu SJ, Chou WC, Ko BS, Tien HF. Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica. 2007;92(1):141\u20132. https:\/\/doi.org\/10.3324\/haematol.10561.","journal-title":"Haematologica"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03802-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:05:31Z","timestamp":1753898731000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3802"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03802-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Verbal consent obtained from the patient. Written informed consent for publication of their clinical details and\/or clinical images was obtained from the patient\u2019s spouse. A copy of the consent form is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}